Immune support and respiratory infection care
Not recommended
Combined enzyme preparations, systemic enzyme therapy (local classification)
ATC code: M01AX-WOBENZYM (Multi-enzyme complex (Wobenzym) – local code)
Brand names
Wobenzym N, Phlogenzym
Wobenzym is a fixed combination of plant and animal proteolytic enzymes with rutoside. Produced by the German company Mucos Pharma; the «systemic enzyme therapy» concept was introduced in the 1960s by Max Wolf and Karl Ransberger. The manufacturer claims anti-inflammatory, anti-oedema, fibrinolytic, and immunomodulatory effects. International rheumatology, phlebology, and sports medicine guidelines do not list the drug. Oral protease bioavailability in the human systemic circulation is limited.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
A combination of proteolytic enzymes (bromelain, papain, pancreatin, trypsin, chymotrypsin) with rutoside. Manufacturers promote such products to boost immunity and ease the course of colds and flu-like infections. Studies have not shown convincing benefit for this use: there is no quality evidence that the combination prevents respiratory infections or speeds up recovery. For a common cold, rest, fluids, and symptom relief are usually enough, and a severe or prolonged course needs a doctor's assessment. The enzyme combination is harmless in this role, but it should not be taken instead of treatment with proven benefit, since that risks missing the care you actually need.
Not recommended
Proteolytic enzyme blends (bromelain, papain, pancreatin, trypsin, chymotrypsin and rutoside) are marketed to athletes as a way to speed recovery and ease muscle soreness after training. Studies have not shown a clear benefit for this use, and there is no solid evidence base behind enzyme blends for sports recovery. What actually helps sore muscles after hard training is well established: enough sleep, adequate protein, and building load up gradually.
Not recommended
For non-clinical complaints of facial and lower-limb oedema, wobenzym is prescribed as an «anti-oedema» agent. Independent RCTs with objective oedema measurement endpoints do not exist. Evidence-based approach to confirmed oedema: differential diagnosis of the cause (heart failure, nephrotic syndrome, venous insufficiency, lymphoedema), then aetiotropic therapy.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Per label, use in pregnancy only with strict indications; international validation is lacking.
Per label, use during breastfeeding is restricted.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Proteolytic enzyme complex (bromelain, papain, pancreatin, trypsin, chymotrypsin, rutoside) is evaluated for the following indications with varying evidence strength: Immune support and respiratory infection care (evidence tier D), Sports recovery (evidence tier D), Symptomatic edema (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Proteolytic enzyme complex (bromelain, papain, pancreatin, trypsin, chymotrypsin, rutoside) (≥ 1 in 100): GI discomfort, flatulence, change in stool odour, Allergic reactions, urticaria, Increased bleeding in patients on anticoagulants. See the Safety section for uncommon and serious reactions.
FDA category N. Per label, use in pregnancy only with strict indications; international validation is lacking.
Per label, use during breastfeeding is restricted.
Proteolytic enzyme complex (bromelain, papain, pancreatin, trypsin, chymotrypsin, rutoside) is contraindicated in: Pregnancy and breastfeeding; Age under 5; Severe coagulation disorders (haemophilia, thrombocytopenia); Concurrent anticoagulants – warfarin, apixaban, rivaroxaban; Hypersensitivity to animal or plant enzymes. Full list in the Safety section.